Epigenetic Target HDAC5 Reduces Environment-Triggered Cocaine Seeking in Rats

The Persistent Challenge of Environment-Triggered Relapse in Stimulant Use Disorder

Managing stimulant use disorders remains a profound clinical challenge, characterized by frequent relapse and an average treatment dropout rate of 30.4% (95% confidence interval, 27.2 to 33.8) across psychosocial interventions [1]. While pharmacological interventions such as prescription psychostimulants increase sustained abstinence rates (relative risk 1.45; 95% confidence interval, 1.10 to 1.92) [2], and therapies like glucagon-like peptide-1 receptor agonists show utility in reducing drug consumption in preclinical models [3, 4], long-term recovery is notoriously difficult to maintain. A major driver of this recurrent cycle is the powerful associative memory linking specific environments to past drug use, which can trigger intense cravings even after prolonged periods of recovery. Functional magnetic resonance imaging (MRI) studies consistently point to dysregulation in prefrontal cortical circuits, specifically the lateral prefrontal cortex and dorsal anterior cingulate cortex, as a core feature of this context reactivity that fundamentally undermines a patient's inhibitory control [5, 6]. Now, a preclinical study details the specific epigenetic mechanisms (changes in gene expression that do not alter the underlying DNA sequence) within the prefrontal cortex that govern these environmental relapse triggers, identifying specific pathways that could eventually serve as pharmacological targets to prevent cue-induced relapse in patients.

Investigating the Molecular Brakes on Environmental Relapse Triggers

In patients with substance use disorders, repeated cocaine use produces neuroadaptations that support drug craving and relapse. Clinically, powerful associations formed with drug use environments can promote a return to active drug use, often overriding conscious intentions to remain abstinent. Despite the clinical impact of these environmental cues, the molecular mechanisms that control the formation of these prepotent drug-context associations remain unclear, leaving physicians with few pharmacological tools to address cue-induced cravings. To investigate the biological underpinnings of this phenomenon, researchers utilized an animal model of intravenous cocaine self-administration using male Sprague Dawley rats. The study specifically examined the role of histone deacetylase 5 (HDAC5), an epigenetic enzyme that regulates gene expression by modifying DNA-associated proteins, in context-associated drug seeking. The investigators focused their analysis on two distinct regions of the medial prefrontal cortex involved in executive function and behavioral inhibition: the prelimbic cortex and the infralimbic cortex. The research team employed a comprehensive suite of techniques to map these pathways. The study utilized viral molecular tools to manipulate gene expression, alongside chemogenetics (a technique using engineered receptors to control specific cell populations with targeted molecules) to isolate behavioral effects. To understand the downstream cellular consequences, the researchers also integrated RNA sequencing to track gene expression changes, electrophysiology to measure the electrical activity of individual neurons, and immunohistochemistry to visualize specific proteins within the brain tissue.

Modulating HDAC5 Alters Context-Specific Cocaine Seeking

The researchers demonstrated that manipulating histone deacetylase 5 (HDAC5) levels directly altered behavioral outcomes in the rat models. Specifically, they found that in the prelimbic cortex, the reduction of endogenous HDAC5 augmented context-associated cocaine seeking. This effect was highly specific to the environmental context of drug use. The reduction of endogenous HDAC5 in the prelimbic cortex did not augment cue-reinstated or drug prime-reinstated cocaine seeking. For clinicians, this distinction is critical because it isolates the epigenetic mechanism to environmental triggers (such as a specific room or location) rather than discrete cues (like drug paraphernalia) or a pharmacological prime (a small dose of the drug itself). Conversely, increasing the presence of this epigenetic enzyme produced a protective effect against environmental triggers. The study found that overexpression of HDAC5 in the prelimbic cortex reduced context-associated cocaine seeking. This anatomical target proved highly specific within the medial prefrontal cortex. When the researchers tested the adjacent brain region, they observed that overexpression of HDAC5 in the infralimbic cortex did not reduce context-associated cocaine seeking. The behavioral suppression driven by this enzyme was strictly limited to the drug context, leaving natural reward pathways intact. The investigators noted that overexpression of HDAC5 in the prelimbic cortex had no effects on sucrose seeking. Furthermore, the timing of this intervention was crucial. The researchers found that prelimbic cortex HDAC5 overexpression following acquisition had no effects on future cocaine seeking, indicating that the enzyme must be active during the initial formation of the memory rather than after the behavior is established. Together, these findings establish that prelimbic cortex HDAC5 has an essential and selective role to limit associations formed in cocaine, but not sucrose, self-administration environments. This selectivity suggests that future pharmacological therapies targeting this pathway could potentially blunt the formation of environmental relapse triggers without blunting a patient's response to natural, healthy rewards.

Shifting the Excitatory-Inhibitory Balance in Prefrontal Circuits

To understand how these behavioral changes manifest at the cellular level, the researchers examined the molecular downstream effects of histone deacetylase 5 (HDAC5) in the prelimbic cortex. The RNA sequencing analysis revealed that HDAC5 and cocaine self-administration altered the expression of numerous prelimbic cortex genes, including many synapse-associated genes. By modifying the transcription of these specific synaptic components, the epigenetic enzyme fundamentally reshaped how neurons in this region communicate. Electrophysiological recordings confirmed this functional shift, demonstrating that HDAC5 significantly increased inhibitory synaptic transmission onto prelimbic cortex deep-layer pyramidal neurons. Because these deep-layer neurons serve as the primary output pathways from the prefrontal cortex to other brain regions, increasing their inhibitory input effectively dampens the outgoing signals that would otherwise drive drug-seeking behavior. This dampening effect was clearly visible when examining overall neuronal activation patterns. When the animals were placed back into the drug-associated context, HDAC5 reduced the induction of FOS-positive neurons in the cocaine self-administration environment. FOS is a well-established protein marker used to identify recently activated neurons, and its reduction indicates a blunted neural response to the environmental trigger. Ultimately, the researchers concluded that prelimbic cortex HDAC5 alters the excitatory and inhibitory balance, possibly through the epigenetic regulation of synaptic genes. By shifting this balance toward inhibition, the prefrontal cortex becomes less reactive to the spatial and contextual memories associated with prior drug use. For clinicians managing patients with substance use disorders, these cellular mechanisms provide a clear biological substrate for the persistent nature of cue-induced cravings. The findings from this study indicate that HDAC5 is positioned as a key factor regulating reward-circuit neuroadaptations that underlie common relapse triggers in substance use disorders. While direct epigenetic therapies for addiction remain in the preclinical stage, identifying the specific molecular brakes that control the excitatory and inhibitory balance in prefrontal circuits offers a concrete target for future pharmacological development. Stabilizing this balance could eventually help physicians prevent environment-triggered relapse without interfering with a patient's capacity to process natural rewards.

References

1. Lappan SN, Brown AW, Hendricks PS. Dropout rates of in-person psychosocial substance use disorder treatments: a systematic review and meta-analysis.. Addiction (Abingdon, England). 2020. doi:10.1111/add.14793

2. Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo TM. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.. Psychopharmacology. 2020. doi:10.1007/s00213-020-05563-3

3. Kim VM, Bastian P, Nicholas BL, Doo-Sup C, Ph. D. The potential role of GLP-1 receptor agonists in substance use disorders – a systematic review. Frontiers in Pharmacology. 2026. doi:10.3389/fphar.2025.1702448

4. Brunchmann A, Thomsen M, Fink-Jensen A. The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.. Physiology & behavior. 2019. doi:10.1016/j.physbeh.2019.03.029

5. Dejoie JM, Senia N, Konova A, Smith DV, Fareri DS. Common and Distinct Drug Cue Reactivity Patterns Associated with Cocaine and Heroin: An fMRI Meta-Analysis. medRxiv. 2023. doi:10.1101/2023.10.19.23297268

6. Luijten M, Machielsen MWJ, Veltman DJ, Hester R, Haan LD, Franken IHA. Systematic review of ERP and fMRI studies investigating inhibitory control and error processing in people. Journal of Psychiatry and Neuroscience. 2014. doi:10.1503/jpn.130052